Christophe Weber, Takeda CEO (Kyodo via AP Images)

Take­da kicks off JPM week with M&A — buy­ing out an­oth­er gam­ma/delta spin­out and div­ing in­to a new ‘swim lane’

Less than 3 months af­ter Take­da scooped up Gam­maDelta in a bid to ex­pand its work on next-gen cell ther­a­pies, the phar­ma gi­ant is back — start­ing off JP Mor­gan week with an­oth­er ac­qui­si­tion in the field.

This time, the buy­out tar­get is Adap­tate Bio­ther­a­peu­tics and its pre­clin­i­cal work on an an­ti­body-based γδ T cell en­gager plat­form, a spin­out from Gam­maDelta that Take­da be­lieves gives them a shot at lead­ing the pack in cell ther­a­pies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.